Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

BioNovelus' CR-10 Part of the Conversation About the Future of Coffee Growing


Posted on: 29 Aug 17

Phoenix, Aug. 29, 2017 (GLOBE NEWSWIRE) -- / FOR IMMEDIATE RELEASE —  The Latin American Symposium on Coffee Production which just concluded in Honduras focused on technological advances in the field of coffee growing in the Central American and Caribbean region. BioNovelus showcased its premiere product, the non-toxic disinfectant and biofungicide CR-10.

“Our participation here is a natural fit,” says BioNovelus CEO and founder, Jean Ekobo. “We are very much part of the conversation of where the future of coffee growing must go.”

Ekobo is referring to BioNovelus’ CR-10, which has proven to be effective in combating coffee rust, an affliction that threatens to eradicate the Arabica Coffee bean by 2080 (John Connor, Climate Institute Director (nrdc.org)) if growers are not strongly proactive in combating it.

The Honduras trip is part of BioNovelus’ plan to continue to increase the Company’s profile in Latin America. In this region, management is positioning the Company’s full product line to play a central part in increasing the productivity of various types of agricultural operations in ways that are both cost-effective and non-harmful to the environment.

“As the population increases and environmental demands become more severe, it becomes ever more important for producers and importers to look at ways of maximizing both their yields and the produce they export. We at BioNovelus are firm in our commitment to bringing our innovative solutions to the largest number of people possible.”

About BioNovelus:
BioNovelus is a bioscience company that honors the environment with innovative, cost effective, and disruptive technology-based solutions to crop protection, food security, and health challenges.

About CR-10 Biofungicide
CR-10 Biofungicide is a proven, biodegradable, non-toxic solution that kills bacteria, fungi, and spores rapidly, safely and effectively. It is a new generation of biofungicide with a unique mode of action. BioNovelus management believes that CR-10 has a broad range of uses in crop protection before harvest.

Forward-Looking Statements
This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for the fiscal year 2017 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
Factors that could cause the Company’s results to differ materially from forward looking statements regarding the efficacy of the crop restoration and results of CR-10  and  registration approval  include the lack of capital needed to complete testing, the lack of experience with pursuing approval of this product and modifications and receipt of information that may be demanded by the registration of the CR-10 formula and the delays in the various government approval processes unrelated to the product itself. Factors that could cause lower rates of success in CR-10 eradication of fungi include the method and timing of applications of CR-10, the impact of heavy rainfall, the strength of fungi contamination, and other environmental conditions resulting in re-infection. Factors that may impact transactions with Mexican and Central American distributors include the alternatives of genetically modified crops, products of competitors, government approvals, and pricing.
There is no assurance of when registrations will be obtained for CR-10 and various applications. There is no assurance that the coffee rust application will prove commercially viable. There is no assurance that any transaction will be done with Mexican and Central American distributors.

Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, general business and economic conditions beyond the Company's control the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, compatibility with other chemical products, the application of the products, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements because of new information, since these statements may no longer be accurate or timely.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

— 30 —

For more information, contact http://bionovelus.com

CONTACT: Media contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. +1 888-924-6668 ext.1 NEkobo@BioNovelus.com Investor Relations: Anthony J. Parkinson, Chief Information Officer BioNovelus, Inc. +1 888-924-6668 ext.3 AParkinson@BioNovelus.com GlobeNewswire
globenewswire.com

Last updated on: 30/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.